STOCK TITAN

DexCom, Inc. - DXCM STOCK NEWS

Welcome to our dedicated page for DexCom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on DexCom stock.

DexCom, Inc. (DXCM) is a leading medical device company founded in 1999, specializing in continuous glucose monitoring (CGM) systems. These systems provide a significant advancement over traditional blood glucose meters, offering real-time glucose readings for diabetic patients. DexCom's innovative CGM technology empowers patients and clinicians to better manage diabetes, contributing to improved health outcomes.

DexCom's flagship products include the Dexcom G6 and the newly developed Dexcom G7 CGM systems. These devices offer features such as customizable alerts, seamless app integration, and data sharing capabilities. The company is also working on integrating their CGM systems with insulin pumps from Insulet and Tandem Diabetes Care, Inc., enabling automatic insulin delivery for more efficient diabetes management.

Recent achievements include the expansion into international markets and the continuous enhancement of their product lineup through research and development. Financially, DexCom has shown robust growth with increasing revenues and solid market performance, reflecting the growing demand for advanced diabetes management solutions.

The company has established strategic partnerships with key players in the medical device industry, further enhancing their market presence and technological capabilities. DexCom is committed to innovation, patient empowerment, and improving the quality of life for people with diabetes worldwide.

Rhea-AI Summary

DexCom (DXCM) has announced preliminary Q4 2024 results with total revenue of at least $1.113 billion, up 8% year-over-year. U.S. revenue reached approximately $803 million (4% growth), while international revenue hit $310 million (17% growth).

Full-year 2024 preliminary revenue totaled $4.032 billion, representing an 11% increase from 2023. The company updated its 2024 guidance, projecting non-GAAP gross profit margin of 62% and operating margin of 19%. Q4 gross margin was negatively impacted by inventory damage during transit and production yield issues.

Looking ahead to 2025, DexCom expects revenue of $4.60 billion, targeting 14% growth. The company forecasts 2025 non-GAAP gross profit margin of 64-65% and operating margin of 21%. Growth drivers include increased CGM access, Stelo rollout, and international expansion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
-
Rhea-AI Summary

DexCom (NASDAQ:DXCM) has announced its upcoming participation at the 43rd Annual J.P. Morgan Healthcare Conference. The company's management will deliver a corporate update presentation on January 13, 2025, at 12:00 PM EST.

The presentation will be accessible through a live webcast, with links available on the Dexcom Investor Relations website at investors.dexcom.com. For those unable to attend live, the presentation will be archived on the website for future viewing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
-
Rhea-AI Summary

Dexcom (NASDAQ:DXCM) has launched the first-ever Generative AI platform in glucose biosensing technology. The platform, built on Google Cloud's Vertex AI and Gemini models, will analyze individual health data patterns to reveal connections between lifestyle choices and glucose levels. Stelo, Dexcom's FDA-cleared over-the-counter glucose biosensor, is the first product to implement this GenAI technology through enhanced Weekly Insights, providing users with personalized recommendations on diet, exercise, and sleep.

The company plans to introduce additional GenAI-powered features throughout the next year to help users better understand their health information and make informed lifestyle decisions. This innovation reinforces Dexcom's position as a leader in glucose biosensing technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
AI
Rhea-AI Summary

The Alberta Government now covers the Dexcom G7 Continuous Glucose Monitoring (CGM) System for eligible residents with type 1 or type 2 diabetes. Dexcom G7 has been added to the Alberta Drug Benefit List, expanding eligibility to include adults aged 18 and older. Residents under 18 must require ongoing insulin or insulin pump therapy, while those 18 and older must use an insulin pump, basal and bolus insulin, or premixed insulin. Dexcom G7 is designed to simplify diabetes management and lower A1C levels. The system offers features like quick sensor warm-up, predictive Urgent Low Soon alerts, and compatibility with various digital health apps. This move aligns Alberta with other Canadian regions, enhancing access to CGM technology. For more information, visit Dexcom's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
-
Rhea-AI Summary

Dexcom (NASDAQ:DXCM) and ŌURA have announced a strategic partnership to integrate Dexcom's glucose biosensor data with ŌURA's health metrics. The partnership includes a $75 million strategic investment from Dexcom in ŌURA's Series D funding, valuing ŌURA at over $5 billion. The companies will enable two-way data flow between their products and launch co-marketing efforts.

The first app integration is expected in the first half of 2025. ŌURA reported selling 2.5 million rings and expects to double annual sales to approximately $500 million in 2024. The partnership aims to provide users with comprehensive metabolic health management by combining glucose data with sleep, stress, heart health, and activity metrics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
partnership
-
Rhea-AI Summary

Dexcom launches a global campaign for World Diabetes Day, revealing that nearly 70% of people with diabetes struggled to start their health journey post-diagnosis, and almost half felt in pursuing their passions. The company's survey across multiple countries shows 85% of respondents believe small steps in diabetes management lead to significant wellbeing improvements, while 84% of tech users affirm that CGM technology helps achieve their dreams. Dexcom is partnering with brand advocates and celebrities to encourage diabetics to share their aspirations on social media, offering a $500 giveaway in the U.S. to help winners start their journey.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
none
Rhea-AI Summary

DexCom (DXCM) reported Q3 2024 financial results with revenue growing 2% year-over-year to $994.2 million. U.S. revenue declined 2% while international revenue grew 12%. GAAP operating income was $152.0 million (15.3% of revenue), showing a 580 basis points decrease compared to Q3 2023. The company launched Stelo, the first over-the-counter glucose biosensor in the U.S. for adults with prediabetes and type 2 diabetes not on insulin therapy. DexCom reiterated its 2024 guidance with expected revenue of $4.00-4.05 billion and announced the retirement of Chief Commercial Officer Teri Lawver at year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
-
Rhea-AI Summary

DexCom, Inc. (NASDAQ:DXCM) has announced its plans to release its third quarter 2024 financial results after market close on Thursday, October 24, 2024. The company will hold a conference call and webcast to review the Q3 2024 performance starting at 4:30 p.m. Eastern Time on the same day.

Investors and interested parties can access the webcast link on the Dexcom investor relations website at investors.dexcom.com, where it will also be archived for future reference. To participate in the conference call, attendees should dial (877) 344-3040 (US/Canada) or (646) 475-1647 (International) and use the confirmation ID "9430114" approximately five minutes before the start time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
conferences earnings
-
Rhea-AI Summary

Dexcom, Beyond Type 2, and actress Retta are establishing National Glucose Awareness Week from Sept. 23-29, 2024. This initiative aims to close the glucose knowledge gap and encourage people to take action on their glucose health. The week will feature educational resources about glucose health and information on new glucose biosensing technology.

A recent survey found that only 10% of people with Type 2 diabetes or prediabetes understand factors affecting their glucose levels well. The initiative includes a nationwide step challenge and opportunities to win prizes while learning about glucose health. Retta, who manages Type 2 diabetes, will inspire others to get involved.

The campaign targets not only those diagnosed with diabetes or prediabetes but also aims to raise awareness among the general population, as one-third of the U.S. population has diabetes or prediabetes, with many unaware of their condition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
Rhea-AI Summary

Dexcom (NASDAQ: DXCM) has launched the third season of Dexcom U, its NIL program for college athletes with diabetes. The 2024 roster includes 20 athletes across 12 sports from 18 colleges, all using Dexcom CGM technology. The program has expanded its mentorship initiatives, including the first-ever Dexcom U Sports Camp, bringing together professional athletes, Dexcom U members, and young athletes with diabetes.

Dexcom U aims to inspire and educate the diabetes community through representation and mentorship. The program provides free educational resources for athletes, parents, coaches, and teammates to better understand diabetes management in sports. Notable additions to the roster include Shelomi Sanders, a basketball player at Alabama A&M, highlighting the program's commitment to diverse representation in collegiate athletics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
none

FAQ

What is the current stock price of DexCom (DXCM)?

The current stock price of DexCom (DXCM) is $86.32 as of January 21, 2025.

What is the market cap of DexCom (DXCM)?

The market cap of DexCom (DXCM) is approximately 34.4B.

What does DexCom, Inc. specialize in?

DexCom, Inc. specializes in continuous glucose monitoring (CGM) systems for diabetic patients.

When was DexCom, Inc. founded?

DexCom, Inc. was founded in 1999.

What are some of DexCom's key products?

Key products include the Dexcom G6 and Dexcom G7 CGM systems.

How do DexCom's CGM systems benefit diabetic patients?

DexCom's CGM systems provide real-time glucose readings, helping patients and clinicians better manage diabetes.

What recent achievements has DexCom made?

Recent achievements include international market expansion and continuous product enhancements.

How is DexCom integrating its CGM systems with other technologies?

DexCom is integrating its CGM systems with insulin pumps from Insulet and Tandem for automatic insulin delivery.

What is the significance of DexCom's strategic partnerships?

Strategic partnerships enhance DexCom's market presence and technological capabilities.

What is DexCom's approach to innovation?

DexCom is committed to innovation, focusing on research and development to advance diabetes management.

How does DexCom support the community?

DexCom empowers patients, caregivers, and clinicians by delivering effective diabetes management solutions.

What financial trends are seen in DexCom's performance?

DexCom has shown robust growth with increasing revenues and strong market performance.
DexCom, Inc.

Nasdaq:DXCM

DXCM Rankings

DXCM Stock Data

34.37B
389.05M
0.31%
97.03%
2.39%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
SAN DIEGO